Pulse Biosciences, Inc. (PLSE) Stock

Pulse Biosciences, Inc. is at the forefront of bioelectric medicine, pioneering innovative solutions to treat a wide range of medical conditions. Central to its offerings is the CellFX System, a sophisticated platform that utilizes Nano-Pulse Stimulation (NPS) technology. This system is distinguished by its ability to deliver precise nano second duration pulses of electrical energy. These pulses are tunable and software-enabled, allowing targeted clearance of cells without causing thermal damage to surrounding non-cellular tissue.

Formerly known as Electroblate, Inc., the company rebranded as Pulse Biosciences, Inc. in December 2015. Since its inception in 2014, Pulse Biosciences has been committed to advancing the field of bioelectric medicine from its headquarters in Hayward, California. The CellFX System represents a significant advancement in medical technology, offering a promising approach to treating various medical conditions through precise and controlled cell elimination.

In addition to its innovative technology platform, Pulse Biosciences continues to expand its research and development efforts. The company aims to leverage its expertise in bioelectric medicine to explore new applications and therapeutic solutions. By focusing on cutting-edge technologies and strategic advancements, Pulse Biosciences remains dedicated to making meaningful contributions to healthcare innovation and patient care.

With a strong foundation in biotechnology and a commitment to scientific excellence, Pulse Biosciences is poised to shape the future of medical treatment. Through its pioneering approach and dedication to advancing therapeutic options, the company strives to improve outcomes for patients worldwide.